AU2001267561A1 - Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents - Google Patents
Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agentsInfo
- Publication number
- AU2001267561A1 AU2001267561A1 AU2001267561A AU6756101A AU2001267561A1 AU 2001267561 A1 AU2001267561 A1 AU 2001267561A1 AU 2001267561 A AU2001267561 A AU 2001267561A AU 6756101 A AU6756101 A AU 6756101A AU 2001267561 A1 AU2001267561 A1 AU 2001267561A1
- Authority
- AU
- Australia
- Prior art keywords
- acid derivatives
- phosphonic acid
- acetylhydroxylaminopropyl
- active agents
- formylhydroxylaminopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to pharmaceutical combination preparations for use in the therapeutical and prophylactic treatment of bacterial and parasitic infections, especially malaria. The inventive preparations contain as the active substances 3-N-formyl-hydroxylaminopropyl phosphonic acid derivatives or 3-N-acetylhydroxylaminopropyl phosphonic acid derivatives combined with other pharmaceutical active agents.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10030781A DE10030781A1 (en) | 2000-06-29 | 2000-06-29 | Combination preparations of 3-N-formylhydroxylaminopropylphosphonic acid derivatives or 3-N-acetylhydroxylaminopropylphosphonic acid derivatives with special active pharmaceutical ingredients |
DE10030781 | 2000-06-29 | ||
PCT/EP2001/007140 WO2002000208A2 (en) | 2000-06-29 | 2001-06-23 | Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined with specific pharmaceutical active agents |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001267561A1 true AU2001267561A1 (en) | 2002-01-08 |
Family
ID=7646647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001267561A Abandoned AU2001267561A1 (en) | 2000-06-29 | 2001-06-23 | Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents |
Country Status (8)
Country | Link |
---|---|
US (2) | US20040235784A1 (en) |
EP (1) | EP1305031B1 (en) |
AT (1) | ATE395064T1 (en) |
AU (1) | AU2001267561A1 (en) |
CA (1) | CA2420640C (en) |
DE (2) | DE10030781A1 (en) |
ES (1) | ES2306718T3 (en) |
WO (1) | WO2002000208A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8088820B2 (en) | 2001-04-24 | 2012-01-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
GB0209262D0 (en) * | 2002-04-23 | 2002-06-05 | Biochemie Gmbh | Organic compounds |
CA2502464A1 (en) * | 2002-10-24 | 2004-05-06 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
US7829126B2 (en) | 2005-10-26 | 2010-11-09 | Abbott Laboratories | Infant formulas containing docosahexaenoic acid and lutein |
US20070166354A1 (en) | 2005-10-26 | 2007-07-19 | Bridget Barrett-Reis | Method of reducing the risk of retinopathy of prematurity in preterm infants |
DE102007026176A1 (en) * | 2007-01-04 | 2008-07-17 | Dewind Ltd. | SCADA unit |
FR2914860B1 (en) * | 2007-04-12 | 2009-05-22 | Ile D Inventeurs Apis Spheromo | MULTILAYER SPHEROIDS WITH ANTIPALUDITIC ACTION IN WHICH ONE OF THE LAYERS CONTAINS ARTESUNATE |
EP2404601A1 (en) | 2010-07-06 | 2012-01-11 | BioAgency AG | New drug combinations for the treatment of Malaria |
EP3235815A1 (en) | 2016-04-19 | 2017-10-25 | Philipps-Universität Marburg | Agents against parasitic helminths |
EP4045056A1 (en) | 2019-10-19 | 2022-08-24 | DMG Deutsche Malaria GmbH | Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives with clindamycin and artesunate |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3715346A (en) * | 1970-11-18 | 1973-02-06 | Upjohn Co | Process for the preparation of lincomycin compounds |
US4330529A (en) * | 1978-02-15 | 1982-05-18 | Fujisawa Pharmaceutical Co., Ltd. | Antibacterial composition |
JPS5746917A (en) * | 1980-09-03 | 1982-03-17 | Fujisawa Pharmaceut Co Ltd | Antibacterial agent |
YU43006B (en) * | 1981-03-06 | 1989-02-28 | Pliva Pharm & Chem Works | Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof |
JPS6064991A (en) * | 1983-09-17 | 1985-04-13 | Fujisawa Pharmaceut Co Ltd | Cephalexin-fosmidomycin salt and its preparation |
US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
US6127405A (en) * | 1998-07-10 | 2000-10-03 | Council Of Scientific And Industrial Research | Method for the use of alpha arteether as an anti-bacterial and anti-fungal agent |
-
2000
- 2000-06-29 DE DE10030781A patent/DE10030781A1/en not_active Ceased
-
2001
- 2001-06-23 ES ES01945307T patent/ES2306718T3/en not_active Expired - Lifetime
- 2001-06-23 US US10/363,280 patent/US20040235784A1/en not_active Abandoned
- 2001-06-23 EP EP01945307A patent/EP1305031B1/en not_active Expired - Lifetime
- 2001-06-23 AT AT01945307T patent/ATE395064T1/en active
- 2001-06-23 DE DE50113974T patent/DE50113974D1/en not_active Expired - Lifetime
- 2001-06-23 CA CA002420640A patent/CA2420640C/en not_active Expired - Fee Related
- 2001-06-23 AU AU2001267561A patent/AU2001267561A1/en not_active Abandoned
- 2001-06-23 WO PCT/EP2001/007140 patent/WO2002000208A2/en active IP Right Grant
-
2015
- 2015-03-16 US US14/659,454 patent/US20150190418A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE10030781A1 (en) | 2002-01-17 |
DE50113974D1 (en) | 2008-06-26 |
EP1305031B1 (en) | 2008-05-14 |
US20150190418A1 (en) | 2015-07-09 |
CA2420640A1 (en) | 2003-02-26 |
WO2002000208A3 (en) | 2002-06-20 |
ATE395064T1 (en) | 2008-05-15 |
US20040235784A1 (en) | 2004-11-25 |
WO2002000208A2 (en) | 2002-01-03 |
CA2420640C (en) | 2009-09-01 |
EP1305031A2 (en) | 2003-05-02 |
ES2306718T3 (en) | 2008-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108532T1 (en) | UNIONS AND COMPOSITIONS FOR PROVIDING ACTIVE AGENTS | |
AU2274201A (en) | Compounds and compositions for delivering active agents | |
AU2002316811A1 (en) | Stable formulation of modified glp-1 | |
PL370111A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
AU2002328972A1 (en) | Piperidine derivatives as antibacterial agents | |
NO971889L (en) | Compounds and compositions for delivery of active agents | |
AU2001296865A1 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
AU2119200A (en) | Medicament | |
AU2001247968A1 (en) | Use of asiatic acid or asiaticoside for treatment of cancer | |
DE602004017871D1 (en) | PREPARATIONS FOR THE TREATMENT OF ARTHRITICAL APPEARANCE | |
WO2002015959A3 (en) | Compounds and compositions for delivering active agents | |
AU2002214389A1 (en) | Pharmaceutical composition containing honey for the treatment of wounds | |
AU2000255628A1 (en) | Formulation comprising thymol useful in the treatment of drug resistant bacterial infections | |
WO2003018059A3 (en) | Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof | |
RS44204A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
AU2001267561A1 (en) | Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents | |
WO2001034641A3 (en) | Antimicrobial activity of the first cationic cluster of human lactoferrin | |
AU2001261516A1 (en) | Semi-solid delivery vehicle and pharmaceutical compositions | |
WO2003009859A1 (en) | Immunotherapy for humans | |
RS44304A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
SE0001916D0 (en) | Novel formulation | |
HUP0204208A2 (en) | Antipruritic agents for external use | |
WO2003007876A3 (en) | N-fatty acid-amino acid conjugates and therapeutic uses | |
EP1273301A3 (en) | Pharmaceutical preparations based on active ingredients susceptible to illict administration | |
BR0011845A (en) | Pharmaceutical complex |